[go: up one dir, main page]

CL2013003785A1 - Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos - Google Patents

Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos

Info

Publication number
CL2013003785A1
CL2013003785A1 CL2013003785A CL2013003785A CL2013003785A1 CL 2013003785 A1 CL2013003785 A1 CL 2013003785A1 CL 2013003785 A CL2013003785 A CL 2013003785A CL 2013003785 A CL2013003785 A CL 2013003785A CL 2013003785 A1 CL2013003785 A1 CL 2013003785A1
Authority
CL
Chile
Prior art keywords
necrostatin
acute
treatment
axonal degeneration
chronic damage
Prior art date
Application number
CL2013003785A
Other languages
English (en)
Inventor
Alarcon Washington Nicolas Martinez
Goldsmith Felipe Alfredo Court
Original Assignee
Univ Pontificia Catolica Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile filed Critical Univ Pontificia Catolica Chile
Priority to CL2013003785A priority Critical patent/CL2013003785A1/es
Publication of CL2013003785A1 publication Critical patent/CL2013003785A1/es
Priority to ARP140104692A priority patent/AR098778A1/es
Priority to PCT/CL2014/000084 priority patent/WO2015100511A1/es
Priority to UY0001035921A priority patent/UY35921A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CL2013003785A 2013-12-30 2013-12-30 Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos CL2013003785A1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CL2013003785A CL2013003785A1 (es) 2013-12-30 2013-12-30 Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos
ARP140104692A AR098778A1 (es) 2013-12-30 2014-12-16 Método y uso de necrostatina-1 para el tratamiento de la degeneración axonal inducida por daños agudos y crónicos
PCT/CL2014/000084 WO2015100511A1 (es) 2013-12-30 2014-12-23 Metodo y uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por danos agudos y cr0nicos
UY0001035921A UY35921A (es) 2013-12-30 2014-12-24 Necrostatina-1 y derivados como retardadores de la degeneración axonal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2013003785A CL2013003785A1 (es) 2013-12-30 2013-12-30 Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos

Publications (1)

Publication Number Publication Date
CL2013003785A1 true CL2013003785A1 (es) 2014-07-11

Family

ID=53492873

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003785A CL2013003785A1 (es) 2013-12-30 2013-12-30 Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos

Country Status (4)

Country Link
AR (1) AR098778A1 (es)
CL (1) CL2013003785A1 (es)
UY (1) UY35921A (es)
WO (1) WO2015100511A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382889B2 (en) 2018-04-19 2022-07-12 Institut D'investigació Biomèdica De Bellvitge (Idibell) NRF2 activators for the prevention and/or treatment of axonal degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633500A1 (en) * 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
US20140357570A1 (en) * 2011-10-21 2014-12-04 Massachusetts Eye And Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders

Also Published As

Publication number Publication date
WO2015100511A1 (es) 2015-07-09
AR098778A1 (es) 2016-06-15
UY35921A (es) 2015-06-30

Similar Documents

Publication Publication Date Title
FIC20250034I1 (fi) O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola
IL246141A0 (en) Methods for adhering tissue surfaces and materials and biomedical uses thereof
DK3116350T3 (da) Rejsepude
BR112016011983A2 (pt) Painel, painel laminado, arranjo de painel, método para produzir o painel e uso do painel
BR112015028171A2 (pt) inibidores de acc e seu uso
FI20135175L (fi) Aktuaattori ja menetelmä aktuaattorin parantamiseksi
BR112015001712A2 (pt) uso de s-pindolol para o tratamento da caquexia e sarcopenia
CO6791602A2 (es) Métodos y sistemas para el tratamiento de pozos
SI3394065T1 (sl) Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega
BR112016008886A2 (pt) Elemento de suporte para o corpo humano
BR112017004451A2 (pt) formulação de tinta de pedra e métodos para produzir a mesma
DK3116897T3 (da) Polymyxinderivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika
BR112014027953A2 (pt) nifuratel- (r), seu uso para o tratamento de infecções e síntese de nifuratel -(r) e -(s)
IL258856A (en) Solabegron zwitterion and uses thereof
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
BR112017003964A2 (pt) folha de topo para artigo absorvente
FI20135019L (fi) Venttiilinnostojärjestely ja menetelmä venttiilinnostojärjestelyn käyttämiseksi
BR112017001384A2 (pt) composto para uso em tratamento anti-helmíntico
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
BR112016021620A2 (pt) compostos e seus métodos de uso
BR112015021722A2 (pt) composição para uso no tratamento de síndrome do ovário policístico
DK3193936T3 (da) Antimikrobielle midler med forøget virkning
ITUB20156000A1 (it) Composizione nematocida e suo utilizzo
ES1094613Y (es) Dispositivo aspirador para la eliminación de parásitos presentes en el cabello.